glp-1 cardiovascular outcomes 2025 news Frontiers Cardiovascular outcomes of semaglutide and
Description
Yes, but with important caveats
Mondot S, de Wouters T, Dore J, Lepage P
11 However, human data remains largely inconclusive, necessitating additional research to establish efficacy and optimal dosage
Our GLP-1 supplement is formulated to be well-tolerated
This is clinically excellent news
